Serum total renin, an independent marker of the activity and severity of retinopathy in patients with IDDM

Sari Mäkimattila, Paula Summanen, Irma Matinlauri, Matti Mäntysaari, Anna Schlenzka, Maija Aalto, Kerri Irjala, Hannele Yki-Järvinen

Abstract

Background/aims—Recent studies have demonstrated marked renin and prorenin concentration gradients between ocular tissues and blood, and local expression of the renin-angiotensin system (RAS) in the eye. The authors determined whether serum total renin, which mostly consists of prorenin, is a marker of the activity and severity of diabetic retinopathy independent of other microvascular complications.

Methods—Total renin concentrations (TRC) were measured with a time resolved immunofluorometric assay in 38 patients with IDDM (age 34 (SD 7) years, duration of disease 22 (7) years, serum creatinine 95 (15) µmol/l, urinary albumin excretion rate (UAER) 207 (829) µg/min, Hba1c 8.5% (1.2%), and in 13 matched normal subjects. All subjects were carefully characterised with respect to the presence and severity of retinopathy (RP score), nephropathy, and neuropathy using seven different tests of autonomic neuropathy.

Results—Serum TRC was on average twofold higher in IDDM (396 (SE 211) ng/l) than in normal subjects (201 (88) ng/l, p<0.001). It was nearly twofold higher in patients with preproliferative or active proliferative retinopathy requiring careful follow up or therapy (TRC 596 (268) ng/l, n=11) compared with those with quiescent proliferative retinopathy after laser treatment (TRC 338 (183) ng/l, p<0.01, n=5); moderately severe non-proliferative retinopathy (337 (106) ng/l, p<0.01, n=13), no retinopathy, or only minimal non-proliferative retinopathy (270 (43) ng/l, p<0.01, n=9). In multiple linear regression analysis, RP score (p<0.01), but not the UAER or any index of autonomic neuropathy, was an independent determinant of serum TRC, and explained 32% of its variation (R=0.57, p<0.005).

Conclusions—Serum TRC in patients with diabetic retinopathy is increased independent of renal function and autonomic neuropathy, especially in those with severe active changes requiring careful follow up or treatment. These findings support the idea that diabetic retinopathy is the most important determinant of serum TRC in patients with IDDM, and that TRC is produced when retinopathy is active.

The aspartyl protease renin is the rate limiting enzyme in the formation of the vasoactive octapeptide angiotensin II. In human blood prorenin, the precursor of renin, constitutes up to 90% of total renin. Classically, renin is considered to be a blood borne enzyme, which is synthesised and secreted from the juxtaglomerular apparatus. However, plasma prorenin is found in nephrectomised subjects in quantities close to those observed in normal individuals. These data suggest that, while circulating renin originates from the kidney, a large proportion of prorenin is produced at extrarenal sites such as adrenals, pituitary, testis, brain, and ovary, as well as some renal and extrarenal tumours.

A marked concentration gradient in prorenin concentrations exists between bovine ocular tissues and blood. This gradient appears to be due to local production of prorenin, which is abundantly expressed in highly vascularised ocular parts such as the retina and choroid. In diabetic patients with proliferative retinopathy, prorenin concentrations in vitreous fluid are 100 times the level expected on the basis of the plasma protein content of ocular fluid. Prorenin concentrations in plasma are also elevated in patients with IDDM and proliferative retinopathy, independent of albuminuria. Thus, the eye could be the major source of elevated prorenin concentrations in IDDM. It is, however, unknown, whether the activity of retinopathy influences prorenin concentrations. In previous studies the classification of retinopathy has only been based on grading of retinopathy to proliferative, background, or no retinopathy.

In the present study we determined whether the serum total renin concentration (TRC) was influenced by severity and activity of diabetic retinopathy itself. Only males were included in
the study since the menstrual cycle is known to influence TRC.7 The severity and activity of retinopathy was graded according to the classification developed for the EURODIAB IDDM Complications Study.14 The presence of nephropathy was determined from the urinary albumin excretion rate and neuropathy by performing seven different tests of autonomic nervous function.

**Methods**

**SUBJECTS AND STUDY DESIGN**

Thirty-eight men with insulin dependent diabetes mellitus (IDDM) and 13 normal men volunteered for the studies. The diabetic patients were recruited from the outpatient clinic based on the following criteria: (1) age 18–50 years, (2) age at diagnosis of diabetes <30 years, (3) an undetectable fasting C peptide concentration (<0.2 nmol/l). The diabetic patients and the normal subjects were matched for age, body mass index (BMI), and body composition (Table 1).

A history, physical examination, and laboratory tests were performed on all subjects to exclude diseases other than diabetes mellitus. All patients and normal subjects had normal blood counts, electrolyte concentrations, and electrocardiograms (data not shown). The diabetic patients were treated with two (n=6), three (n=5), four (n=22), five (n=1), or six (n=1) injections of a combination of intermediate and short acting insulins. Four patients were using continuous subcutaneous insulin infusion therapy. The mean insulin doses are shown in Table 1. The patients did not take any other medication than insulin. The experimental protocol adhered to the principles of the Declaration of Helsinki, and was approved by the ethics committee of the Helsinki University Central Hospital. Informed written consent was obtained.

In each patient, the presence of microvascular complications was assessed as described below. A blood sample for measurement of serum TRC was taken at the time of fundus photography. The subjects were allowed to rest in supine position before the blood sample was drawn, and the serum for measurement of TRC was subsequently stored at −20°C. Three timed overnight urine collections for measurement of the urinary albumin excretion rate (UAER) were performed immediately before retinal photography. The autonomic function tests were performed on a separate occasion within a month from fundus photography and the UAER measurements.

**RETINAL PHOTOGRAPHS**

The presence and severity of activity of diabetic retinopathy was assessed using two 45° fundus colour slides representing macular and disc/nasal field15 taken from each eye through dilated pupils. Photographs were graded in a masked fashion by an ophthalmologist (PS) based on the classification developed for the EURODIAB IDDM Complications Study.14 For each eye, the maximum grade of the diabetic lesions, microaneurysms, haemorrhages, lipid exudates, intraretinal microvascular abnormalities, retinal microinfarcts, venous beading, new vessels, vitreous and preretinal haemorrhages, was determined to produce an overall severity level for an eye (RP score) (Table 2). The score of the more severely affected eye was used to represent a patient. All patients who were found to have active neovascularisation in spite of previous laser treatment were re-examined and given further laser therapy (PS). Active new neovascularisation was judged from the presence of curly neovascular vessels along the retinal surface. These vessels were often adjacent to previous laser scars. In contrast with this, in inactive proliferative retinopathy only dense laser scars with or without fibrous proliferations and no open vessels were seen.

**TABLE 1 Characteristics of the study groups**

<table>
<thead>
<tr>
<th></th>
<th>Normal subjects (n=13)</th>
<th>IDDM patients (n=38)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>34 (8)</td>
<td>34 (7)</td>
</tr>
<tr>
<td>Duration of diabetes (years)</td>
<td>—</td>
<td>22 (7)</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>25.3 (3.2)</td>
<td>24.7 (2.4)</td>
</tr>
<tr>
<td>Body fat (%)</td>
<td>17 (4)</td>
<td>17 (5)</td>
</tr>
<tr>
<td>HBA₁ (%)</td>
<td>5.2 (0.5)</td>
<td>8.5 (1.2)***</td>
</tr>
<tr>
<td>Serum triglycerides (mmol/l)</td>
<td>1.1 (0.4)</td>
<td>1.0 (0.3)</td>
</tr>
<tr>
<td>Serum cholesterol (mmol/l)</td>
<td>4.8 (0.6)</td>
<td>4.5 (0.9)</td>
</tr>
<tr>
<td>Urinary albumin excretion (µg/min)</td>
<td>9 (4)</td>
<td>207 (620)***</td>
</tr>
<tr>
<td>Serum creatinine (mmol/l)</td>
<td>93 (10)</td>
<td>95 (15)</td>
</tr>
<tr>
<td>Blood pressure, systolic (mm Hg)</td>
<td>126 (18)</td>
<td>126 (14)</td>
</tr>
<tr>
<td>Blood pressure, diastolic (mm Hg)</td>
<td>92 (15)</td>
<td>76 (8)</td>
</tr>
<tr>
<td>Insulin dose (IU/m/d)</td>
<td>—</td>
<td>0.84 (0.24)</td>
</tr>
</tbody>
</table>

**TABLE 2 Retinopathy severity grading scale***

<table>
<thead>
<tr>
<th>Level</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level 10</td>
<td>No retinopathy/MA and all other lesions absent.</td>
</tr>
<tr>
<td>Level 20</td>
<td>Minimal/mild non-proliferative retinopathy: MA only; or small retinal dot haemorrhages indistinguishable from MAs only; HMA &lt;SP1; with or without lipid exudates.</td>
</tr>
<tr>
<td>Level 30</td>
<td>Moderate non-proliferative retinopathy: HMA ≥SP2A in one field; or HMA &lt;SP 2A with IRMA, and/or RMI both &lt;SP 8A; VB &lt;SP6A, or &gt;SP6A in only one vein.</td>
</tr>
<tr>
<td>Level 40</td>
<td>Severe non-proliferative retinopathy: HMA ≥SP 2A in both fields, or if only in one field with IRMA or RMI both ≥SP 8A; or VB &gt;SP 6A in two veins or more.</td>
</tr>
<tr>
<td>Level 50</td>
<td>Inactive/quiescent proliferative retinopathy: No evidence of active new vessels cut some retinopathy changes of level 20–30 changes possible as well as fibrous proliferation with photocoagulation scars either in scatter or confluent patches (panretinal photocoagulation).</td>
</tr>
<tr>
<td>Level 60</td>
<td>Active proliferative retinopathy: New vessels on the disc and/or the retina with or without scars of photocoagulation.</td>
</tr>
</tbody>
</table>

MA=microaneurysm; H=haemorrhage; SP=standard photograph (ETDRS); RMI=retinal microinfarct; IRMA=intraretinal microvascular abnormalities; VB=venous beading.
Subjects | IDDM none to minimal non-proliferative retinopathy (RP score 10, 20) | IDDM moderate non-proliferative retinopathy (RP score 30) | IDDM quiescent proliferative retinopathy (RP score 50) | IDDM severe non-proliferative or active proliferative retinopathy (RP score 40, 60)
---|---|---|---|---
Normal subjects | 13 | 9 | 13 | 5 | 11
Age (years) | 34 (8) | 29 (6)* | 35 (7) | 36 (7) | 36 (7)
Duration of diabetes (years) | 16 (6)** | 21 (8) | 25 (5) | 25 (4) | 25 (4)
Body mass index (kg/m²) | 25.3 (3.2) | 24.5 (2.1) | 24.2 (3.1) | 19 (6) | 16 (4)
Body fat (%) | 17 (5) | 17 (5) | 19 (6) | 16 (4) | 16 (4)
HbA₁c (%) | 5.2 (0.5)** | 7.8 (0.8)**, † | 8.8 (1.4) | 7.8 (0.8) | 9.2 (1.0)
Urinary albumin excretion (µg/min) | 9 (3) | 7 (3) | 10 (9) | 208 (349)** | 602 (1495)**
Blood pressure, systolic (mmHg) | 126 (18) | 120 (11) | 122 (11) | 128 (7) | 133 (19)
Insulin dose (IU/m²/day) | 0.75 (0.28) | 0.94 (0.27) | 0.80 (0.20) | 0.81 (0.16) | 0.75 (0.28)
Serum total renin (ng/l) | 201 (88)**, † | 270 (43) | 337 (106) | 338 (183) | 596 (268)**, ††

***p<0.001 for normal subjects vs IDDM patients; ††p<0.01 for IDDM patients with RP score 30, 40, or 60; †††p<0.001 for IDDM patients with RP score 30 or 40 or 60 vs other IDDM patients, †p<0.05 for IDDM patients with RP score 10 or 20 vs patients with RP score 30 or 40, †††p<0.001 for IDDM patients with RP score 10 or 20 vs patients with RP score 30 or 50, †††p<0.001 for normal subjects vs IDDM patients with RP score 30, 40, or 60, †††p<0.001 for IDDM patients with RP score 30 or 40 or 60 vs patients with RP score 30 or 40 or 60; †††p<0.001 for IDDM patients with RP score 30 or 40 vs patients with RP score 30 or 50; †p<0.05 for normal subjects vs IDDM patients with RP score 10 or 20 or 50. Data are expressed as mean and standard deviation of the mean (SD).

Valsalva test, and the orthostatic test. In the controlled breathing test, a measure of both para-
sympathetic and sympathetic inputs into heart rate control,15 a quiet sound signal was given to
pace the inspiration and expiration for 2
seconds each. This pattern was maintained for
5 minutes, during which the R-R intervals were
measured from the electrocardiogram. The
square root of the mean of the square of
successive R-R interval differences (RMSSD)
was calculated. The frequency domain analysis
of heart rate variability was done using spectral
analysis of R-R interval variability using the
CAPFTS system (Medico Oy, Kuopio,
Finland). After detrending the R-R interval
signal, a least square autoregressive model with a model order of 14 was used to
obtain the power spectral estimate of R-R
interval variability. The total power (TP) was
determined in the frequency range from 0 to
0.5 times heart rate in Hz. Low frequency
power (LF) was determined in the frequency
range from 0.04 to 0.15 Hz, and it is thought to
be mediated by both parasympathetic and
sympathetic pathways.16 17 High frequency
power (HF) was determined in the frequency
range from 0.15 to 0.40 Hz, and it is thought to
be mediated by parasympathetic pathways.16 17
The signal powers were calculated as integrals
under the respective part of the power spectral
density function, and were expressed in abso-
lute units (ms²), and in relation (LF/HF) as a
measure of “sympathovagal balance”.16 18 In
the deep breathing test, a test of vagal heart rate
control,15 the duration of inspiration and expira-
tion was 5 seconds for both for 40 seconds
(four respiratory cycles). The ratio of the long-
est and shortest R-R intervals was determined
from the electrocardiogram for each respira-
tory cycle, and the mean of the four ratios was
taken as the expiration to inspiration ratio (E/I
ratio). In the Valsalva test, a measure of both
parasympathetic and sympathetic function,19
the subjects blew into a manometer thereby
maintaining an intrathoracic pressure of 40
mm Hg for 15 seconds. The ratio of the short-
est R-R interval during the inspiratory strain
and the longest R-R interval during the 20 sec-
onds after the end of the strain was calculated
(Valsalva ratio). In the orthostatic test the
subjects stood up after resting quietly supine
for 5 minutes. Heart rate and blood pressure
were measured at rest and 1, 3, 5, and 7
minutes after standing up.

STAGING OF DIABETIC NEPHROPATHY
Three timed overnight urine collections were
obtained in the diabetic patients and once in
the normal subjects to classify the subjects
according to their UAER (Table 1). Nor-
moalbuminuria was defined as an UAER
below 20 µg/min, microalbuminuria between
20 and 200 µg/min, and macroalbuminuria as
a rate over 200 µg/min in at least two out of
the three consecutive overnight urine samples.20

SERUM TOTAL RENIN CONCENTRATION
The TRC in serum was measured with a modifi-
cation of a time resolved immunofluoro-
metric assay.21 The method was based on a
sandwich type immunoassay with two mono-
clonal anti-human renin antibodies (clones
R3-27-6 and R3-36-16, Ciba-Geigy, Basel,
Switzerland). Preparation of renin (code 68/
356; National Institute for Biological Stand-
ards and Control, Herts) was used to calibrate
the renin standards. Within assay precision
(CV) was 2.1% at the renin concentration of
100 ng/l (n=12), and 1.4% at the renin
concentration of 750 ng/l (n=12). Between
assay precision was 5.0% at the renin concen-
tration of 130 ng/l (n=6), and 3.2% at the renin
centration of 1320 ng/l (n=6). All serum
TRC measurements were performed at least 1
month after photocoagulation (mean 2 years,
range 1 month–6 years, n=10).

OTHER MEASUREMENTS
Glycated haemoglobin (HbA₁c) was measured
by high performance liquid chromatography22
using the fully automated glycosylated haemo-
globin analyser System (BioRad, Richmond,
CA, USA). Urine albumin was measured by an
immunoturbidimetric (Hitachi 911, Tokyo,
Japan) method using an antiserum against
human albumin (Orion Diagnostica, Espoo,
Finland). Serum creatinine was determined by
enzymatic kinetic analysis using Jaffe’s reaction
in a multichannel automatic analyser
(Hitachi). Body composition was determined

Table 3 Characteristics of the IDDM patients grouped by the severity of the diabetic retinopathy

<table>
<thead>
<tr>
<th>Retinopathy and total renin in IDDM</th>
<th>Normal subjects</th>
<th>IDDM none to minimal non-proliferative retinopathy (RP score 10, 20)</th>
<th>IDDM moderate non-proliferative retinopathy (RP score 30)</th>
<th>IDDM quiescent proliferative retinopathy (RP score 50)</th>
<th>IDDM severe non-proliferative or active proliferative retinopathy (RP score 40, 60)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects</td>
<td>13</td>
<td>9</td>
<td>13</td>
<td>5</td>
<td>11</td>
</tr>
<tr>
<td>Age (years)</td>
<td>34 (8)</td>
<td>29 (6)*</td>
<td>35 (7)</td>
<td>36 (7)</td>
<td>36 (7)</td>
</tr>
<tr>
<td>Duration of diabetes (years)</td>
<td>16 (6)**</td>
<td>21 (8)</td>
<td>25 (5)</td>
<td>25 (4)</td>
<td>25 (4)</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>25.3 (3.2)</td>
<td>24.5 (2.1)</td>
<td>24.2 (3.1)</td>
<td>19 (6)</td>
<td>16 (4)</td>
</tr>
<tr>
<td>Body fat (%)</td>
<td>17 (5)</td>
<td>17 (5)</td>
<td>19 (6)</td>
<td>16 (4)</td>
<td>16 (4)</td>
</tr>
<tr>
<td>HbA₁c (%)</td>
<td>5.2 (0.5)**</td>
<td>7.8 (0.8)**, †</td>
<td>8.8 (1.4)</td>
<td>7.8 (0.8)</td>
<td>9.2 (1.0)</td>
</tr>
<tr>
<td>Urinary albumin excretion (µg/min)</td>
<td>9 (3)</td>
<td>7 (3)</td>
<td>10 (9)</td>
<td>208 (349)**</td>
<td>602 (1495)**</td>
</tr>
<tr>
<td>Blood pressure, systolic (mmHg)</td>
<td>126 (18)</td>
<td>120 (11)</td>
<td>122 (11)</td>
<td>128 (7)</td>
<td>133 (19)</td>
</tr>
<tr>
<td>Insulin dose (IU/m²/day)</td>
<td>0.75 (0.28)</td>
<td>0.94 (0.27)</td>
<td>0.80 (0.20)</td>
<td>0.81 (0.16)</td>
<td>0.75 (0.28)</td>
</tr>
<tr>
<td>Serum total renin (ng/l)</td>
<td>201 (88)**, †</td>
<td>270 (43)</td>
<td>337 (106)</td>
<td>338 (183)</td>
<td>596 (268)**, ††</td>
</tr>
</tbody>
</table>
by using bioelectrical impedance (Bio-Electrical Impedance Analyzer System, Model #BIA-101A, Mf Clemens, MI, USA).^{23}

**STATISTICAL METHODS**

Data between the two study groups were compared using the Student’s t test. Data between more than two groups were compared using analysis of variance (ANOVA) followed by pairwise comparison using Fisher’s least significant difference test. Differences between urinary albumin excretion rates were compared using the Mann–Whitney rank sum test. Simple correlations between selected study variables were calculated using Spearman’s rank correlation coefficient. Multiple linear regression analysis was used to analyse the causes of variation in variables of serum total renin, retinopathy level, UAER, and autonomic neuropathy. Total renin and UAER were log transformed to normalise their distribution for multiple linear regression analysis. All calculations were made using the SYSTAT statistical package (Systat Inc, Evanston, IL, USA). All data are expressed as means and standard deviation of mean (SD).

**Results**

**DIABETIC RETINOPATHY AND SERUM TOTAL RENIN**

To examine the effect of the severity and activity of the diabetic retinal vascular changes on serum TRC, the diabetic patients were divided into four groups according to the need of treatment of diabetic retinopathy (Table 3). Serum TRC was significantly higher in all IDDM groups compared with the normal subjects (Table 3). Serum TRC was twofold higher in patients with preproliferative or active proliferative retinopathy requiring careful follow up or laser therapy (596 (SD 268) ng/l) compared with patients with previously laser treated quiescent proliferative retinopathy (338 (183) ng/l, p<0.01), those with moderately severe non-proliferative retinopathy (337 (106) ng/l, p<0.01), or patients with no or only minimal non-proliferative retinopathy (270 (43) ng/l, p<0.001, n=9) (Fig 1).

**INTERRELATION BETWEEN SERUM TOTAL RENIN, RETINOPATHY, AND OTHER MICROVASCULAR COMPLICATIONS**

In simple regression analysis, RP score (r=0.53, p<0.001), HbA<sub>1c</sub> (r=0.40, p<0.05), and duration of diabetes (r=0.36, p<0.05) were positively correlated with total renin. Serum TRC was not correlated with UAER, systolic or diastolic blood pressure, heart rate, or results of other autonomic function tests. In multiple linear regression analysis, RP score (p<0.01), but not the UAER or any index of autonomic neuropathy, was an independent determinant of serum TRC, and explained 32% of its variation (R=0.57, p<0.005).

**Discussion**

In the present study, compared with normal subjects, patients with IDDM as one group or divided in four groups according to severity and activity of retinopathy had significantly higher serum TRC. The increase in TRC was independent of other microvascular complications. Serum TRC were nearly twofold higher in patients with preproliferative or active proliferative retinopathy requiring careful follow up or therapy than in those with laser treated quiescent proliferative retinopathy. These data provide evidence for a relation between serum TRC and severity and activity of diabetic retinopathy. They extend the previous findings by demonstrating that even mild signs of diabetic retinopathy are associated with increased concentrations of prorenin, and that TRC are higher in active than inactive proliferative retinopathy.

In simple regression analysis, in addition to RP score, duration of diabetes and HbA<sub>1c</sub>, those with previously laser treated quiescent proliferative retinopathy. Furthermore, the lack of an arteriovenous concentration difference across the kidney in diabetic patients with high prorenin and end stage kidney disease is consistent with

---

**Table 4 Results of autonomic nervous system tests in the study groups**

<table>
<thead>
<tr>
<th>Test</th>
<th>Variable</th>
<th>Normal subjects (n=8)</th>
<th>IDDM patients (n=35)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controlled breathing</td>
<td>RMSSD (ms)</td>
<td>38.3 (13.7)</td>
<td>30.3 (35.0)</td>
</tr>
<tr>
<td>Controlled breathing</td>
<td>TP (ms&lt;sup&gt;2&lt;/sup&gt;)</td>
<td>2969 (2438)</td>
<td>1860 (4397)</td>
</tr>
<tr>
<td>Controlled breathing</td>
<td>LF (ms&lt;sup&gt;2&lt;/sup&gt;)</td>
<td>545 (300)</td>
<td>398 (630)</td>
</tr>
<tr>
<td>Controlled breathing</td>
<td>HF (ms&lt;sup&gt;2&lt;/sup&gt;)</td>
<td>618 (366)</td>
<td>427 (488)</td>
</tr>
<tr>
<td>Controlled breathing</td>
<td>LF/HF ratio</td>
<td>1.0 (0.7)</td>
<td>1.5 (1.5)</td>
</tr>
<tr>
<td>Deep breathing</td>
<td>E/I ratio</td>
<td>1.3 (0.1)</td>
<td>1.3 (0.2)</td>
</tr>
<tr>
<td>Valsalva manoeuvre</td>
<td>Valsalva ratio</td>
<td>1.9 (0.3)</td>
<td>1.7 (0.3)*</td>
</tr>
<tr>
<td>Orthostatic test, 7 minutes</td>
<td>Systolic blood pressure decrease</td>
<td>−2.9 (10.0)</td>
<td>−5.6 (12.3)</td>
</tr>
</tbody>
</table>

*<p<0.05 for IDDM patients vs normal subjects. Data are expressed as mean (SD).

RMSSD = square root of the mean of the square of R-R interval differences.

TP = total power.

LF = low frequency.

HF = high frequency component of heart rate variability in spectral analysis.
the idea that serum prorenin is of extrarenal origin in patients with IDDM. Franken et al.24,25 also showed, again in keeping with the present data, that retinopathy, particularly the proliferative type, was an independent determinant of abnormally high plasma renin, independent of the presence of neuropathy and nephropathy.

Prorenin in vitreous fluid from eyes of diabetic patients with traction retinal detachment is up to 100-fold higher relative to albumin and other plasma proteins, and higher than in non-diabetic subjects with recurrent retinal detachment complicated by proliferative vitreoretinopathy.14 The highest renin and prorenin concentrations are found in the order: subretinal fluid > vitreous > aqueous humour.12 The exact location of prorenin production is unknown, although renin mRNA expression has recently been found using RNase protection assay in pooled retinal pigment epithelium-choroid samples, but not RNAse protection assay in pooled retinal epithelium.28

Prorenin and total renin in IDDM

the idea that serum prorenin is of extrarenal origin in patients with IDDM. Franken et al.24,25 also showed, again in keeping with the present data, that retinopathy, particularly the proliferative type, was an independent determinant of abnormally high plasma renin, independent of the presence of neuropathy and nephropathy.

Prorenin in vitreous fluid from eyes of diabetic patients with traction retinal detachment is up to 100-fold higher relative to albumin and other plasma proteins, and higher than in non-diabetic subjects with recurrent retinal detachment complicated by proliferative vitreoretinopathy.14 The highest renin and prorenin concentrations are found in the order: subretinal fluid > vitreous > aqueous humour.12 The exact location of prorenin production is unknown, although renin mRNA expression has recently been found using RNase protection assay in pooled retinal pigment epithelium-choroid samples, but not RNAse protection assay in pooled retinal epithelium.28

Prorenin in the pathogenesis of diabetic retinopathy

Mean TRC was significantly higher in patients with severe non-proliferative or active proliferative retinopathy than in those with quiescent laser treated proliferative retinopathy. On the basis of our pilot study, it would be tempting to speculate that TRC could be helpful in identifying patients with persistent active proliferation or new neovascularisation years after panretinal photocoagulation.

Supported by grants from the Academy of Finland (HY), the Sigrid Juselius Foundation (HY) and the Finnish Diabetes Research Foundation (PS).

We thank Ms Kati Tuomola and Ms Sari Hämäläinen for excellent technical assistance, Mr Ronald Klein, for valuable help in the planning of the grading of fundus photographs, Ms Soile Aarnio for drawing the figure and the volunteers for their help.

Serum total renin, an independent marker of the activity and severity of retinopathy in patients with IDDM

Sari Mäkimattila, Paula Summanen, Irma Matinlauri, Matti Mäntysaari, Anna Schlenzka, Maija Aalto, Kerttu Irjala and Hannele Yki-Järvinen

doi: 10.1136/bjo.82.8.939

Updated information and services can be found at:
http://bjo.bmj.com/content/82/8/939

These include:

References
This article cites 33 articles, 15 of which you can access for free at:
http://bjo.bmj.com/content/82/8/939#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Retina (1608)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/